𝔖 Bobbio Scriptorium

✦ LIBER ✦

Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin

✍ Scribed by G. Montalescot; J.P. Collet; M.L. Tanguy

Book ID: 113414594
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 41 KB
Volume: 13
Category: Article
ISSN: 1062-1458
DOI: 10.1016/j.accreview.2004.10.060

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Heparin-associated anti-Xa activity and

Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome

✍ Richard C. Becker; Kenneth W. Mahaffey; Hongqiu Yang; A. J. Marian; Mark I. Furm 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 403 KB

Efficacy and Safety of Fondaparinux Vers

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines: Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial

✍ Sanjit S. Jolly; David P. Faxon; Keith A.A. Fox; Rizwan Afzal; William E. Boden; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 847 KB

ANTI-INFLAMMATORY ACTIVITY AND COX-1 REC

ANTI-INFLAMMATORY ACTIVITY AND COX-1 RECEPTOR COMPETITION IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION TREATED WITH NONSELECTIVE COX-INHIBITOR AND LOW-DOSE ASPIRIN

✍ Nikita Lomakin; Alexie K. Gruzdev 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 238 KB

TCT-502 Efficacy and safety of switching

TCT-502 Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

✍ Pérez de Prado, Armando; Cid, Belen; Saez, Pilar Carrillo; Diego, Alejandro; Cue 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 281 KB

Safety and Efficacy of Switching From Ei

Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial

✍ Harvey D. White; Derek P. Chew; James W. Hoekstra; Chadwick D. Miller; Charles V 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 228 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB